First dual inhibitors of human topoisomerase IIα and Hsp90 C-terminal domain inhibit the growth of Ewing sarcoma in vitro and in vivo
Povzetek
Heat shock protein 90 (Hsp90) and topoisomerase IIα (TopoIIα) are members of the GHKL protein superfamily, both with clinically validated roles as anticancer drug targets. We report the discovery of the first class of dual inhibitors targeting the ATP-binding site of TopoIIα and the C-terminal domain of Hsp90, displaying potent cancer growth inhibition both in vitro and in vivo. Initially, a known TopoIIα inhibitor, compound 3, was shown to bind to the C-terminal domain of Hsp90, but not to its ATP-binding N-terminal domain. Nineteen analogs were then prepared and evaluated to investigate the structure–activity relationships, several of which inhibited the growth of SK-N-MC Ewing sarcoma cells in vitro. Compound 3 emerged as one of the most potent growth inhibitors (IC50 = 0.33 ± 0.04 µM), demonstrating the ability to induce apoptosis and cell cycle arrest in SK-N-MC cells in vitro, and to slow the growth of Ewing sarcoma in vivo in a zebrafish model.
Ključne besede
cancer;Ewing sarcoma;Hsp90;inhibitor;topoisomerase IIα;zebrafish;
Podatki
| Jezik: | Angleški jezik |
|---|---|
| Leto izida: | 2024 |
| Tipologija: | 1.01 - Izvirni znanstveni članek |
| Organizacija: | UL FFA - Fakulteta za farmacijo |
| UDK: | 616-006 |
| COBISS: |
209903875
|
| ISSN: | 0045-2068 |
| Št. ogledov: | 40 |
| Št. prenosov: | 4 |
| Ocena: | 0 (0 glasov) |
| Metapodatki: |
|
Ostali podatki
| Sekundarni jezik: | Slovenski jezik |
|---|---|
| Sekundarne ključne besede: | Rak (medicina);Sarkom; |
| Vrsta dela (COBISS): | Članek v reviji |
| Strani: | 20 str. |
| Letnik: | ǂVol. ǂ153 |
| Zvezek: | ǂart. ǂ107850 |
| Čas izdaje: | 2024 |
| DOI: | 10.1016/j.bioorg.2024.107850 |
| ID: | 25300991 |
Priporočena dela:
First dual inhibitors of human topoisomerase IIα and Hsp90 C-terminal domain inhibit the growth of Ewing sarcoma in vitro and in vivo
2024,
ni podatka o podnaslovu
Optimisation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as novel Hsp90 C-terminal domain inhibitors against Ewing sarcoma
2022,
ni podatka o podnaslovu
Exploration and optimisation of structure-activity relationships of new triazole-based C-terminal Hsp90 inhibitors towards in vivo anticancer potency
2024,
ni podatka o podnaslovu
Sarkomi
2011,
doktrinarna načela zdravljenja in klinične poti
Structure-activity relationships of benzothiazole-based Hsp90 C-terminal-domain inhibitors
2021,
ni podatka o podnaslovu